Advertisement

Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer

Published:February 23, 2017DOI:https://doi.org/10.1016/j.clinimag.2017.02.003

      Highlights

      • Imaging should guide the best treatment options for biochemical recurrence PCa after primary treatment.
      • From our findings, FCH PET/CT should be preferred to CT and BS
      • These results have promising implications in BMT directed therapies and potential effects on a patient's quality of life.
      • More studies are needed to compare FCH PET/CT with either MRI or new radiopharmaceutical agents in PCa patients with BMTs.

      Abstract

      Purpose

      The aim of our study is to evaluate the prognostic impact of 18F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse.

      Methods

      We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5 months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy. Two independent observers reviewed FCh-PET/CT and MDP-BS images. The bone window of CT portion from FCh-PET/CT was separately assessed. Time to progression (TTP), skeletal event free survival (SES) and cancer specific survival (CSS) were defined as the length of time between imaging and progression of disease, skeletal related events and cancer specific mortality, respectively. A patient based and a K agreement analysis was used to compare the findings of all three imaging modalities. Kaplan-Meier and log-rank analysis were computed for survival assessment. A multivariate Cox regression analysis was used to identify the independent predictors for TTP.

      Results

      Bone metastases were detected in 22 (38%) patients at FCh-PET/CT, in 27 (47%) at MDP-BS and in 24 (41%) at CT. The agreement between FCh-PET/CT and MDP-BS, CT and MDP-BS, and FCh-PET/CT and CT were moderate/fair (respectively, k: 0.474, 0.267 and 0.424; all p < 0.05). After 38 months (IQR: 27–54 months) of follow-up, 33 (57%) patients had a new recurrence of disease, 12 (21%) had skeletal related events and 19 (33%) died. Three subjects (5%) were lost during the observational period. At survival analyses, a worse TTP, SES and CSS were found in patients with a positive FCh-PET/CT at bone level than those with a negative scan (all p ≤ 0.05). Conversely, any significant difference in TTP, SES and CSS was found for patients with both a positive MDP-BS and CT scan. At univariate analysis, a positive FCh-PET/CT at skeletal level was associated with all events (all p < 0.05). However, only a positive FCh-PET/CT at any site was an independent prognostic variable of TTP (HR: 3.08; CI 95%: 1.85–9.05; p = 0.04).

      Conclusions

      PET/CT should be preferred to CT and BS in patients with prostate cancer with bone metastasis because it allows a better stratification of TTP, SES and CCS compared to CT and BS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
        • Moschini M.
        • Sharma V.
        • Zattoni F.
        • Quevedo J.F.
        • Davis B.J.
        • Kwon E.
        • et al.
        Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy.
        Eur Urol. 2016; 69: 135-142
        • Shen G.
        • Deng H.
        • Hu S.
        • Jia Z.
        Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.
        Skeletal Radiol. 2014; 43: 1503-1513
        • Pasoglou V.
        • Larbi A.
        • Collette L.
        • Annet L.
        • Jamar F.
        • Machiels J.P.
        • et al.
        One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach?.
        Prostate. 2014; 74: 469-477
        • Azad G.K.
        • Cook G.J.
        Multi-technique imaging of bone metastases: spotlight on PET-CT.
        Clin Radiol. 2016; 71: 620-631
        • Tamam C.
        • Tamam M.
        • Mulazimoglu M.
        The accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of bone lesions of undetermined origin.
        World J Nucl Med. 2016; 15: 124-129
        • Heidenreich A.
        • Bastian P.J.
        • Bellmunt J.
        • Bolla M.
        • Joniau S.
        • van der Kwast T.
        • et al.
        EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer.
        Eur Urol. 2014; 65: 467-479
        • Saad F.
        • Gleason D.M.
        • Murray R.
        • Tchekmedyian S.
        • Venner P.
        • Lacombe L.
        • et al.
        A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
        J Natl Cancer Inst. 2002; 94: 1458-1468
        • Saad F.
        • Gleason D.M.
        • Murray R.
        • Tchekmedyian S.
        • Venner P.
        • Lacombe L.
        • et al.
        Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
        J Natl Cancer Inst. 2004; 96: 879-882
        • Scher H.I.
        • Fizazi K.
        • Saad F.
        • Taplin M.E.
        • Sternberg C.N.
        • Miller K.
        • et al.
        Increased survival with enzalutamide in prostate cancer after chemotherapy.
        N Engl J Med. 2012; 367: 1187-1197
        • Logothetis C.J.
        • Basch E.
        • Molina A.
        • Fizazi K.
        • North S.A.
        • Chi K.N.
        • et al.
        Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
        Lancet Oncol. 2012; 13: 1210-1217
        • Cohen J.
        Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.
        Psychol Bull. 1968; 70: 213-220
        • Sim J.
        • Wright C.C.
        The kappa statistic in reliability studies: use, interpretation, and sample size requirements.
        Phys Ther. 2005; 85: 257-268
        • Altamn D.
        Practical statistics for medical research.
        Chapman & Hall/CRC, 1991
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • Schultz D.
        • Blank K.
        • Broderick G.A.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • Weinstein M.
        • Tomaszewski J.E.
        • Schultz D.
        • et al.
        Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.
        J Urol. 2001; 166: 2185-2188
        • Evangelista L.
        • Zattoni F.
        • Guttilla A.
        • Saladini G.
        • Zattoni F.
        • Colletti P.M.
        • et al.
        Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
        Clin Nucl Med. 2013; 38: 305-314
        • Decaestecker K.
        • de Meerleer G.
        • Ameye F.
        • Fonteyne V.
        • Lambert B.
        • Joniau S.
        • et al.
        Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
        BMC Cancer. 2014; 14: 671
        • Picchio M.
        • Spinapolice E.G.
        • Fallanca F.
        • Crivellaro C.
        • Giovacchini G.
        • Gianolli L.
        • et al.
        [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
        Eur J Nucl Med Mol Imaging. 2012; 39: 13-26
        • Beheshti M.
        • Langsteger W.
        Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients.
        Eur J Nucl Med Mol Imaging. 2012; 39 ([author reply 2-3]): 910-911
        • Giovacchini G.
        • Incerti E.
        • Mapelli P.
        • Kirienko M.
        • Briganti A.
        • Gandaglia G.
        • et al.
        (11C)Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.
        Eur J Nucl Med Mol Imaging. 2015; 42: 877-884
        • Giovacchini G.
        • Picchio M.
        • Garcia-Parra R.
        • Briganti A.
        • Abdollah F.
        • Gianolli L.
        • et al.
        11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
        J Nucl Med. 2014; 55: 233-241
        • Etchebehere E.C.
        • Araujo J.C.
        • Fox P.S.
        • Swanston N.M.
        • Macapinlac H.A.
        • Rohren E.M.
        Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival.
        J Nucl Med. 2015; 56: 1177-1184
        • Beheshti M.
        • Vali R.
        • Waldenberger P.
        • Fitz F.
        • Nader M.
        • Hammer J.
        • et al.
        The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
        Mol Imaging Biol. 2009; 11: 446-454
        • Rigatti P.
        • Suardi N.
        • Briganti A.
        • da Pozzo L.F.
        • Tutolo M.
        • Villa L.
        • et al.
        Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
        Eur Urol. 2011; 60: 935-943
        • Passoni N.M.
        • Suardi N.
        • Abdollah F.
        • Picchio M.
        • Giovacchini G.
        • Messa C.
        • et al.
        Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
        Urol Oncol. 2014; 32: 38 e9-38 16
        • Suardi N.
        • Gandaglia G.
        • Gallina A.
        • di Trapani E.
        • Scattoni V.
        • Vizziello D.
        • et al.
        Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
        Eur Urol. 2015; 67: 299-309
        • Zattoni Fabio
        • Nehra Avinash
        • Murphy Christopher R.
        • Rangel Laureano
        • Mynderse Lance
        • Lowe Val
        • et al.
        Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post–radical prostatectomy.
        Eur Urol Focus. 2016; https://doi.org/10.1016/j.euf.2016.01.008
        • Tree A.C.
        • Khoo V.S.
        • Eeles R.A.
        • Ahmed M.
        • Dearnaley D.P.
        • Hawkins M.A.
        • et al.
        Stereotactic body radiotherapy for oligometastases.
        Lancet Oncol. 2013; 14: e28-e37
        • Muacevic A.
        • Kufeld M.
        • Rist C.
        • Wowra B.
        • Stief C.
        • Staehler M.
        Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer.
        Urol Oncol. 2013; 31: 455-460
        • Ahmed K.A.
        • Barney B.M.
        • Davis B.J.
        • Park S.S.
        • Kwon E.D.
        • Olivier K.R.
        Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.
        Front Oncol. 2012; 2: 215
        • Decaestecker K.
        • de Meerleer G.
        • Lambert B.
        • Delrue L.
        • Fonteyne V.
        • Claeys T.
        • et al.
        Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
        Radiat Oncol. 2014; 9: 135
        • Sartor O.
        • Coleman R.
        • Nilsson S.
        • Heinrich D.
        • Helle S.I.
        • O'Sullivan J.M.
        • et al.
        Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
        Lancet Oncol. 2014; 15: 738-746
        • Guttilla A.
        • Bortolami A.
        • Evangelista L.
        Prostate cancer as a chronic disease: cost-effectiveness and proper follow-up.
        Q J Nucl Med Mol Imaging. 2015; 59: 439-445